Radar · Oncology in Germany
Best Oncology Companies in Germany
The 155 best Oncology companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CureVac.
By Rohit KhannaTrends & Stories
155companies tracked
$5.9Bdisclosed funding
0unicorns
74have raised
Germany's oncology sector has 155 tracked companies and $5.9B in disclosed funding behind them, and that stack tells you something real about where European cancer drug development is concentrating right now. ITM leads the directory at $681M raised, Tubulis Technologies has pulled in $214M, and the spread between those two and the rest of the field is wide enough to matter. No unicorns yet, but the funding trajectory is hard to ignore: the global oncology market sits at roughly $250.9B today and is forecast to reach $668.3B by 2034 at an 11.5% CAGR, driven by precision medicine expansion and rising cancer incidence. Germany's cluster is positioned squarely inside that wave.
So what's moving the needle this quarter? Hot themes in coverage are cancer biomarkers, angiogenesis inhibitors, and counseling oncology, and I'd say that mix signals a maturing market, one shifting from pure drug discovery toward diagnostics and patient support infrastructure. AI's growing role in oncology genetics is accelerating that shift globally, and Germany's research-heavy ecosystem is well placed to benefit. Cost-containment policies remain a structural headwind you can't ignore, particularly for smaller portfolio companies below the ITM tier. Investors like HTGF and Bayern Kapital are the ones writing the early checks here, and their continued activity suggests the pipeline stays active into 2025 and beyond.
Sources & further reading
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
FLIAR INTELLIGENCE · ONCOLOGY × GERMANY
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
498kcombined LinkedIn audience
78%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CureVac Developer of mRNA-based therapeutics against cancer and infectious diseases 55Patents top 20%Funding top 28%Moat top 29%Innovation top 32% All 11 signals ▾Patentstop 20% Fundingtop 28% Moattop 29% Innovationtop 32% Partnerstop 41% Markettop 43% Newstop 45% Talenttop 49% Techbottom 49% Globalbottom 46% Growthbottom 38% Patents: 1,737 patents matched (strict assignee match) · 461 filings since 2022 vs 745 in 2017-21 Funding: Raised $975M across 14 rounds · 14 rounds over 23 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $975M | 69 mo ago | 648 648 → 678 (+5%) | 2000 | Florian Mulbe Co-Founder & CPO | 14 signals ▼55% M&A · Regulatory · Earnings | 1,737 patents mRNA therapeutics and vaccine delivery via lipid nanoparticle platforms | — |
| 2 | BioNTech Developer of immunotherapeutics for the treatment of cancer and other diseases 78Patents top 7%Innovation top 17%News top 26%Tech top 28% All 13 signals ▾Patentstop 7% Innovationtop 17% Newstop 26% Techtop 28% Globaltop 28% Fundingtop 29% Talenttop 29% Growthtop 33% Moattop 35% Producttop 39% Markettop 48% Partnersbottom 43% Fin. healthbottom 42% Patents: 2,228 patents matched (strict assignee match) · 1521 filings since 2022 vs 431 in 2017-21 Innovation: 2,228 patents (top 1% of patent-holders) · 1521 filings since 2022 vs 431 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $806M | 50 mo ago | 4,530 4,530 → 5,204 (+15%) | 2008 | Christoph Huber Co-Founder & Managing Director | 26 signals Leadership · Announcements · M&A | 2,228 patents mRNA vaccine formulation, nucleic acid therapeutics, and immune‑checkpoint cancer combo technologies | 1 partnership |
| 3 | MorphoSys Developer of antibodies for treating cancer | $770M | 68 mo ago | 732 | 1992 | Andreas Pluckthun Co-Founder | — | 1,338 patents Therapeutic antibody engineering, formulation, and purification processes for targeted immunotherapies | — |
| 4 | ITM Developer of radiopharmaceuticals and radioisotopes for cancer treatment 27Funding top 25%Growth top 35%Moat top 42%Global top 48% All 9 signals ▾Fundingtop 25% Growthtop 35% Moattop 42% Globaltop 48% Talenttop 50% Marketbottom 38% Techbottom 26% Newsbottom 20% Fin. healthbottom 10% Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $681M | 12 mo ago | 54 | 2004 | Oliver Buck Founder | — | — | 1 award |
| 5 | CatalYm Developer of drugs for the treatment of cancer 37Funding top 24%Moat top 28%Patents top 42%Innovation top 45% All 9 signals ▾Fundingtop 24% Moattop 28% Patentstop 42% Innovationtop 45% Growthtop 48% Globalbottom 39% Marketbottom 33% Techbottom 33% Newsbottom 17% Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $261M | 23 mo ago | 18 | 2016 | — | — | 23 patents Therapeutic anti‑GDF15 antibodies for neoadjuvant and combination cancer treatment | — |
| 6 | Immatics Developer of T -cell-based immunotherapies for the treatment of cancer 76Product top 14%Funding top 23%News top 23%Patents top 30% All 10 signals ▾Producttop 14% Fundingtop 23% Newstop 23% Patentstop 30% Techtop 31% Growthtop 32% Moattop 32% Innovationtop 39% Markettop 41% Globaltop 50% Product: 6 distinct product lines · Company stage: Public Funding: Raised $236M across 7 rounds · 7 rounds over 22 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 76/100 | $236M | 34 mo ago | 198 | 2000 | — | 9 signals ▲80% Leadership · Funding · Earnings | 43 patents Engineering and selection of antigen-specific T cells for adoptive immunotherapy | — |
| 7 | Tubulis Technologies Developer of antibody-drug conjugates for the treatment of cancer 60News top 15%Funding top 18%Growth top 20%Patents top 27% All 10 signals ▾Newstop 15% Fundingtop 18% Growthtop 20% Patentstop 27% Moattop 28% Innovationtop 35% Talenttop 50% Marketbottom 42% Globalbottom 42% Techbottom 32% News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $214M | 8 mo ago | 33 | 2015 | Dominik Schumacher Co-Founder & CEO | 13 signals ▲333% M&A · Funding · Leadership | 70 patents Phosphorus‑based linkers for antibody‑drug conjugates targeting cancer antigens | — |
| 8 | Ganymed Pharmaceuticals Developer of antibody-based drugs for the treatment of solid cancers | $212M | 151 mo ago | 4 | 2001 | — | — | 1,019 patents Targeted antibody therapeutics against claudin‑6 and claudin‑18.2 for oncology | — |
| 9 | T-Knife Developer of tumor-specific T cell receptor therapies for the treatment of cancer | $188M | 58 mo ago | 8 | 2018 | Elisa Kieback Co-Founder & CEO | — | 20 patents Engineered T‑cell immunotherapy constructs: chimeric CD8/CD95 receptors and KRAS‑specific TCRs | 1 expansion |
| 10 | Glycotope Developer of Glyco-optimized antibodies and provider of contract research and manufacturing services. | $166M | 128 mo ago | 116 | 2001 | Steffen Goletz CEO | — | 495 patents Recombinant surfactant protein D production and anti‑MUC1 antibody therapeutics | — |
| 11 | iOmx Developer of checkpoint modulators for treating cancer | $120M | 56 mo ago | 33 33 → 53 (+61%) | 2016 | — | — | — | — |
| 12 | Vivoryon Developer of therapeutic agents for age related disorders 45Funding top 19%News top 29%Growth top 47%Market top 49% All 7 signals ▾Fundingtop 19% Newstop 29% Growthtop 47% Markettop 49% Talentbottom 49% Globalbottom 39% Techbottom 29% Funding: Raised $112M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) News: 4 BI events in 12 mo (of 6 tracked, 3 types) · Top themes: Earnings, Funding rank vs industry peers · Fliar Intelligence Index 45/100 | $112M | 8 mo ago | 100 | 1997 | Ulrich Dauer CEO | 4 signals Earnings · Funding | — | — |
| 13 | Emergence Therapeutics Developer of immunotherapeutics for treating cancer | $98M | 54 mo ago | 10 | 2019 | — | — | 45 patents Patents concentrated in health & consumer products | — |
| 14 | Noxxon Pharma Developer of aptamers to target the tumour microenvironment | $93M | 53 mo ago | 13 | 1997 | — | — | 362 patents Nucleic‑acid chemokine modulators and polyalkoxylation methods for cancer therapeutics | — |
| 15 | Affimed Therapeutics Developer of antibody therapeutic solutions for cancer treatment | $90M | 137 mo ago | 197 | 2000 | Adi Hoess CEO | — | 56 patents Engineered multivalent antibody fragments targeting CD16 and EGFRvIII for immune cell engagement | — |
| 16 | Medigene Developer of T cell immunotherapies for haematological malignancies 62Product top 14%Patents top 32%Funding top 34%Innovation top 37% All 12 signals ▾Producttop 14% Patentstop 32% Fundingtop 34% Innovationtop 37% Fin. healthtop 38% Growthtop 40% Moattop 41% Markettop 42% Partnerstop 45% Techbottom 44% Globalbottom 44% Newsbottom 26% Product: 5 distinct product lines · Company stage: Public Patents: 341 patents matched (strict assignee match) · 4 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 25 mo ago | 114 | 1994 | — | — | 341 patents Patents concentrated in health & consumer products | — |
| 17 | Apogenix Developer of novel protein therapeutics for the treatment of cancer and inflammatory diseases | $72M | 54 mo ago | 57 | 2005 | — | — | 369 patents Engineered multi-specific protein agonists for immune checkpoint modulation and cancer therapy | — |
| 18 | Topas Therapeutics Developer of nanoparticle-based therapeutics for immunology disorders | $69M | 58 mo ago | 14 14 → 21 (+50%) | 2016 | — | — | 54 patents Targeted nanoparticle delivery systems for antigens and viral vectors in immunotherapy | — |
| 19 | InflaRx Developer of antibody therapeutics for inflammatory and immune diseases | $64M | 104 mo ago | 56 56 → 47 (-16%) | 2008 | Renfeng Guo Co-Founder | 6 signals ▲500% Earnings · Announcements · Incorporation | 152 patents C5a complement receptor antagonists (small molecules and antibodies) for inflammatory disease therapy | — |
| 20 | Epigenomics Molecular Diagnostics for Cancer | $53M | 65 mo ago | 32 | 1998 | Greg Hamilton CEO | — | 793 patents DNA methylation‑based liquid biopsy biomarkers for early cancer detection and prognosis | — |
| 21 | Ariceum Therapeutics Developer of drugs for systemic targeted radiation therapy to treat cancer | $52M | 38 mo ago | 26 | 2021 | Manfred Ruediger CEO | — | 21 patents Alpha‑emitting somatostatin‑receptor radiopharmaceuticals for targeted cancer therapy. | — |
| 22 | Abalos Therapeutics Developer of anticancer therapies by stimulating arenavirus | $51M | 56 mo ago | 22 | 2019 | Marcus Kostka CEO | — | 38 patents Oncolytic arenavirus vectors engineered for enhanced tumor cell entry and therapy | — |
| 23 | U3 Pharma Antibody-based protein therapies primarily for cancer | $49M | 241 mo ago | — | 2001 | Johannes Bange CEO | — | 214 patents HER3-targeted antibody‑drug conjugates and nucleic‑acid biomarker diagnostics | — |
| 24 | GPC Biotech Developing oncology therapies | $44M | 228 mo ago | — | 1997 | Elmar Maier Co-Founder | — | 128 patents Developing kinase inhibitor small molecules and hybrid screening assays for cancer therapy. | — |
| 25 | 4SC Mid-stage Biotech company discovering & developing small molecule cancer therapies based on epigenetic… | $42M | 123 mo ago | 48 | 1997 | — | — | 621 patents Novel small‑molecule kinase and Kv1.3 ion‑channel inhibitors for cancer immunotherapy | — |
| 26 | Breakpoint Therapeutics Provider anti-cancer drug based on DNA repair mechanism | $34M | 83 mo ago | 5 | 2019 | — | — | 15 patents Inhibiting DNA repair enzymes (polymerase θ, Werner helicase) for cancer therapeutics | — |
| 27 | CPTx Developer of programmable DNA therapeutics for a range of medical challenges 40Growth top 35%Funding top 37%Moat top 38%Talent top 38% All 9 signals ▾Growthtop 35% Fundingtop 37% Moattop 38% Talenttop 38% Techtop 46% Patentstop 50% Innovationbottom 43% Globalbottom 31% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $29.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $29M | 20 mo ago | — | 2021 | Christian Sigl Founder & CTO | — | 4 patents Peptide and nucleic‑acid therapeutic formulations and delivery methods | — |
| 28 | Tacalyx Developer of therapeutic agents for cancer treatment 16News top 32%Growth top 35%Funding top 37%Moat top 47% All 9 signals ▾Newstop 32% Growthtop 35% Fundingtop 37% Moattop 47% Patentsbottom 38% Globalbottom 37% Marketbottom 25% Techbottom 23% Innovationbottom 21% News: 4 BI events in 12 mo (of 6 tracked, 2 types) · Top themes: Leadership, Funding Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 16/100 | $23M | 1 mo ago | 9 | 2018 | — | 4 signals Leadership · Funding | 2 patents Glycoengineered therapeutic antibodies targeting Globo H cancer antigens | — |
| 29 | DISCO Pharmaceuticals Developer of target-directed therapeutic modalities for the treatment of cancer 40Growth top 28%Funding top 36%News top 36%Talent top 38% All 9 signals ▾Growthtop 28% Fundingtop 36% Newstop 36% Talenttop 38% Partnerstop 40% Moattop 42% Globalbottom 39% Marketbottom 35% Techbottom 17% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $21.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $22M | 6 mo ago | — | 2022 | Johannes Heuckmann Chief Operating Officer (COO) and founder | 3 signals Contracts · Funding | — | — |
| 30 | T-CURX Developer of immune-based cancer treatments with T-cells 27Funding top 40%Moat top 45%Patents bottom 49%Talent bottom 49% All 6 signals ▾Fundingtop 40% Moattop 45% Patentsbottom 49% Talentbottom 49% Globalbottom 40% Innovationbottom 36% Funding: Raised $21.4M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $21M | 6 mo ago | — | 2016 | Christian Sollner Founder | — | 5 patents Non‑viral gene delivery vectors and engineered immune cells for therapeutic applications | — |
| 31 | Heidelberg Pharma Provider of preclinical services specializing in ADCs (Antibody Drug Conjugates) | $20M | 74 mo ago | 113 | 1999 | Andreas Pahl CEO & Sprecher des Vorstands at Heidelberg Pharma AG | 8 signals ▼56% Earnings · Leadership · Announcements | 422 patents Antibody‑drug conjugates employing amatoxin toxins and cleavable linkers for cancer therapy | — |
| 32 | Mainz BioMed Provider of diagnostic kits for colorectal cancer 40Funding top 36%Tech top 45%News top 47%Patents top 48% All 10 signals ▾Fundingtop 36% Techtop 45% Newstop 47% Patentstop 48% Marketbottom 49% Moatbottom 49% Talentbottom 49% Innovationbottom 46% Growthbottom 42% Globalbottom 32% Funding: Raised $17.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Tech: 35 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 40/100 | $17M | 4 mo ago | 64 | 2021 | Guido Baechler CEO | 5 signals ▼62% Funding · Announcements · Earnings | 7 patents Predictive biomarkers for colorectal adenoma and cancer progression risk assessment | 2 launchs · 1 partnership · 1 expansion |
| 33 | Pentixa pharm Provider of support services for early stage radiopharmaceutical projects | $17M | 76 mo ago | 10 | 2019 | — | 4 signals ▼88% Earnings · IPO · Announcements | — | — |
| 34 | BEBIG Medical Provider of radiation therapy products for cancer treatment and care | $16M | 29 mo ago | — | 1992 | Julian Schroder Co-CEO | — | — | — |
| 35 | Amcure Development of a novel compound for the treatment of metastasizing cancers | $13M | 114 mo ago | 7 | 2011 | — | — | 42 patents Therapeutic cyclic peptides targeting CD44v6 for cancer and angiogenesis treatment | — |
| 36 | Myelo Therapeutics Small molecules to treat chemotherapy-induced myelosuppression | $13M | 42 mo ago | 10 | 2013 | — | — | 8 patents Imidazole-based radioprotective compounds for treating lethal radiation exposure symptoms | — |
| 37 | Kupando Developer of immunotherapeutics for cancer 11News top 32%Funding top 40%Moat top 48%Talent bottom 41% All 6 signals ▾Newstop 32% Fundingtop 40% Moattop 48% Talentbottom 41% Globalbottom 37% Marketbottom 23% News: 4 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership Funding: Raised $12.6M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 11/100 | $13M | 3 mo ago | 5 | 2018 | Johanna Holldack Founder & CEO | 4 signals Funding · Leadership | — | — |
| 38 | Micromet Antibody-based therapies for the treatment of cancer | $10M | 212 mo ago | 15 | 1993 | — | — | 354 patents Bispecific single-chain antibody engineering for targeted immunotherapy, especially CD19×CD3 therapeutics. | — |
| 39 | MELAGENIX Developer of molecular diagnostic tests to detect skin cancer | $9M | 75 mo ago | 9 | 2017 | Daniel Janowski Co-Founder & CPO | — | — | — |
| 40 | Akribion Therapeutics Developer of RNA-guided technology with applications in cancer therapy and other indications 16Talent top 28%Funding top 47%Global bottom 48%Market bottom 25% All 5 signals ▾Talenttop 28% Fundingtop 47% Globalbottom 48% Marketbottom 25% Techbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $8.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $8M | 16 mo ago | — | 2024 | Michael Krohn Co-Founder & Co-CEO | — | — | — |
| 41 | Jenlab Developer of multiphoton tomography and fluorescence lifetime imaging microscopy technology | $6M | 59 mo ago | — | 2017 | Karsten Koenig CEO | — | 36 patents Multimodal optical imaging, laser dental hard‑tissue machining, and flow‑based tumor cell detection | — |
| 42 | PROSION Developer of precision medicine technology for cancer treatment | $6M | 50 mo ago | 10 | 2020 | Mutlu Yonel Co-Founder | — | — | — |
| 43 | Epignostix Developer of DNA methylation-based therapeutics for tumor classification | $5M | 23 mo ago | — | 2022 | Daniel Schrimpf Co-Founder | — | — | — |
| 44 | Eisbach Developer of targeted therapy for cancer treatment | $5M | 27 mo ago | 13 | 2019 | Adrian Schomburg Co-Founder & CEO | — | — | — |
| 45 | Umlaut.bio Developer of small-molecule therapeutics for cancer 32Growth top 35%Funding top 44%Talent bottom 49%Tech bottom 48% All 6 signals ▾Growthtop 35% Fundingtop 44% Talentbottom 49% Techbottom 48% Globalbottom 37% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $3.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $4M | 3 mo ago | — | 2022 | Karsten Fischer CEO | — | — | — |
| 46 | TME Pharma Developer of novel therapies to treat cancer | $3M | 47 mo ago | 13 | 1998 | — | 6 signals ▼40% Funding · Fundraising · Contracts | — | — |
| 47 | Dermagnostix Developer of molecular diagnostic tests for skin diseases | $3M | 42 mo ago | 24 | 2018 | — | — | 25 patents Patents concentrated in transport & manufacturing processes | 1 job opening · 1 partnership |
| 48 | Thericon Developer of image diagnostic device for the diagnosis of bladder cancer | $3M | 48 mo ago | — | 2019 | Nikolaos Deliolanis Co-Founder & CEO | — | — | — |
| 49 | RAYDIAX Developer of therapy-assist CT system for minimally invasive interventions 24Talent top 23%Funding top 41%Global bottom 32%Market bottom 26% All 4 signals ▾Talenttop 23% Fundingtop 41% Globalbottom 32% Marketbottom 26% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated Funding: Raised $2.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $3M | 3 mo ago | 9 | 2021 | Tim Pfeiffer Co-Founder | — | — | 1 job opening · 1 award |
| 50 | Oncgnostics Developer of epigenetic biomarkers for cancer detection and diagnosis | $1M | 33 mo ago | 12 12 → 19 (+58%) | 2012 | — | — | 22 patents Molecular diagnostic assays for cancer risk assessment, especially head‑and‑neck oncology | — |
Top 12 Oncology companies in Germany
#1
Series E · Munich, Bavaria · founded 2004 · 54 employees$681Mraised▾
Series E · Munich, Bavaria · founded 2004 · 54 employees
Developer of radiopharmaceuticals and radioisotopes for cancer treatment. The company's lead product is radionuclide therapy candidate LuCaFab (ITM-31) for the treatment of malignant brain tumors. The company offers medical isotopes like EndolucinBeta and TOCscan. It also offers radiolabelling and quality control equipment like iQS - Theranostics Synthesizer, iQS Ga-68, Fluidic Labeling, Module Reagent Set Manual, and 177Lu Labeling.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 25%Growth
top 35%Moat
top 42%Global
top 48%Talent
top 50%Market
bottom 38%Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) · Last round Conventional Debt (May 2025)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 5/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 4.7% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- May 2025Conventional Debt$262.5M
- Jun 2024Series E$204.4M
- Jun 2023Series E$273M
- Mar 2022Series D$36.4M
Founders & team
Investors
Temasek, BlackRock, Qatar Investment Authority, Carbyne Equity Partners, ATHOS, European Investment Bank
Tech stack
Apache Http ServerBootstrapIonosJqueryLightboxMatomo Analytics
#2
Acquired · Munich, Bavaria · founded 2015 · 33 employees$214.1Mraised▾
Acquired · Munich, Bavaria · founded 2015 · 33 employees
Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
News
top 15%Funding
top 18%Growth
top 20%Patents
top 27%Moat
top 28%Innovation
top 35%News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY · 12 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series C (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 3.6% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series C$401M
- Mar 2024Series B$138.8M
- Aug 2022Grant (prize money)—
- May 2022Series B$63.1M
Founders & team
Investors
Nextech Invest, Deep Track Capital, Frazier Life Sciences, Andera Partners, BioMedPartners, Bayern Kapital
Tech stack
All-InklApache Http ServerBorlabs CookieCore-JsElementorJquery
#3
Seed · Berlin, Berlin · founded 2018 · 9 employees$22.8Mraised▾
Seed · Berlin, Berlin · founded 2018 · 9 employees
Tacalyx is developing therapeutic agents for cancer treatment. The lead products are developed to target cancer-specific carbohydrate antigens that are located on the surface of metastatic malignant tumors (TACAs and other related cell surface glycans).
Fliar Intelligence Index™ 16how this company ranks against its industry peers
News
top 32%Growth
top 35%Funding
top 37%Moat
top 47%Patents
bottom 38%Global
bottom 37%News: 4 BI events in 12 mo (of 6 tracked, 2 types) · Top themes: Leadership, Funding
Growth: Fresh capital in last 24 mo
Funding: Raised $22.8M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Seed (Apr 2026)
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Biotechnology Innovation Organization (BIO)) announced in 12 mo
Funding rounds
- Apr 2026Seed$12.9M
- Jun 2024Seed$15.1M
- Sep 2019Seed$7.7M
Investors
Boehringer Ingelheim Venture Fund, Kurma Partners, Creathor Venture, Coparion, Idinvest Partners, HTGF
Tech stack
Closure LibraryGoogle Font ApiIonosLit-ElementLit-HtmlMicrosoft 365
#4
Public · Halle, Saxony Anhalt · founded 1997 · 100 employees$112.2Mraised▾
Public · Halle, Saxony Anhalt · founded 1997 · 100 employees
Vivoryon Therapeutics is developing therapeutic agents for treating age-related diseases. The company leading candidate is PQ912 is in phase 2a of the clinical trial and is for Alzheimer's disease and Cancer, other candidates of the company are PQxxx and PQ1565 which is in the preclinical stage and effective against cancer and other diseases. Theses are small molecule-based and inhibit QTCPL. The company has developed glutaminyl cyclase enzyme inhibitors which is a key enzyme in Alzheimer’s disease and cancer.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 19%News
top 29%Growth
top 47%Market
top 49%Talent
bottom 49%Global
bottom 39%Funding: Raised $112M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) · Last round Post IPO (Oct 2025)
News: 4 BI events in 12 mo (of 6 tracked, 3 types) · Top themes: Earnings, Funding
Growth: Headcount 100 → 100 (+0%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$6M
- May 2023Post IPO$26.8M
- Oct 2019Post IPO$47.8M
- Oct 2016Post IPO$16.7M
Founders & team
Investors
Andera Partners, Bmp Ventures, IBG Beteiligungsgesellschaft Sachsen-Anhalt, Life Sciences Partners, HBM Partners, EQT
Tech stack
All-InklContact Form 7CookieyesJqueryJquery MigrateJquery Ui
#5
Series A · Schonefeld, Brandenburg · founded 2018 · 5 employees$12.6Mraised▾
Series A · Schonefeld, Brandenburg · founded 2018 · 5 employees
Developer of immunotherapeutics for cancer. It offers a lead candidate KUP101 an immunostimulatory agent co-encapsulated in a liposomal formulation for the treatment of solid tumors in combination with other drugs.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
News
top 32%Funding
top 40%Moat
top 48%Talent
bottom 41%Global
bottom 37%Market
bottom 23%News: 4 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership
Funding: Raised $12.6M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series A (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 552 LinkedIn followers
Funding rounds
- Mar 2026Series A$11.5M
- Sep 2022Series A$12.6M
Founders & team
Investors
Remiges Ventures, LifeCare Partners, Brandenburg Capital, HTGF, Ventura Biomed, CARMA FUND
#6
Public · Mainz, Rhineland-Palatinate · founded 2021 · 64 employees$17.3Mraised▾
Public · Mainz, Rhineland-Palatinate · founded 2021 · 64 employees
Provider of diagnostic kits for colorectal cancer. The company's product ColoAlert is a PCR-based molecular genetic colorectal cancer early-detection stool test. It uses proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 36%Tech
top 45%News
top 47%Patents
top 48%Market
bottom 49%Moat
bottom 49%Funding: Raised $17.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Post IPO (Feb 2026)
Tech: 35 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Hsts, Http/3
News: 5 BI events in 12 mo (of 33 tracked, 5 types) · -62% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 145 LinkedIn followers
Activity (LinkedIn): 2 product launches · 1 partnerships · 1 expansions announced in 12 mo
Funding rounds
- Feb 2026Post IPO$3M
- Jun 2023Post IPO$14.3M
Founders & team
#7
Series A · Wurzburg, Bavaria · founded 2016$21.4Mraised▾
Series A · Wurzburg, Bavaria · founded 2016
T-CURX is developing immune-based cancer treatments with T-cells. They are developing new generation UltraModularCAR T cells (transformative, chemotherapy-free treatment) for treating leukemia, lymphoma, breast cancer, and lung cancer. It's in phase I/II a clinical trial for safety and efficacy evaluation.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 40%Moat
top 45%Patents
bottom 49%Talent
bottom 49%Global
bottom 40%Innovation
bottom 36%Funding: Raised $21.4M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) · Last round Series A (Dec 2025)
Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents
Patents: 5 patents matched (strict assignee match) · 3 filings since 2022 vs 2 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Britiel Cancer Institute (BCI)) announced in 12 mo
Funding rounds
- Dec 2025Series A$20.8M
- Jan 2018Grant (prize money)$605.1K
Founders & team
Investors
Europa, BioMedPartners, Bayern Kapital, Hlc Fund, i and iBio Fund
#8
Seed · Cologne, North Rhine Westphalia · founded 2022$21.9Mraised▾
Seed · Cologne, North Rhine Westphalia · founded 2022
Developer of target-directed therapeutic modalities for the treatment of cancer. The company specializes in mapping the surfaceome of cancer cells and develop first-in-class cancer drugs. It identifies proteins and protein communities across the entire cancer cell surface addressing the need for target candidates for both mono- and bi-specific antibodies.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Growth
top 28%Funding
top 36%News
top 36%Talent
top 38%Partners
top 40%Moat
top 42%Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $21.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (Dec 2025)
News: 3 BI events in 12 mo (of 3 tracked, 2 types) · Top themes: Contracts, Funding
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · hiring: BTA/MTA (m/f/d), Financial Accountant – Accounting & Administration
Activity (LinkedIn): 1 partnerships (incl. Amgen) announced in 12 mo
Funding rounds
- Dec 2025Seed$41.9M
- Jan 2024Seed$21.9M
Founders & team
Investors
Sofinnova Partners, Panakes Partners, M Ventures, AbbVie, Ackermans & van Haaren, NRW.Bank
Tech stack
Apache Http ServerIonosJqueryJquery MigrateLightboxMicrosoft 365
#9
Series A · Magdeburg, Saxony Anhalt · founded 2021 · 9 employees$2.5Mraised▾
Series A · Magdeburg, Saxony Anhalt · founded 2021 · 9 employees
Developer of therapy-assist CT system for minimally invasive interventions. The company offers a CT-guided therapy device that uses a navigation system and a combination of 2D and 3D X-ray live imaging for minimally invasive tumor interventions.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Talent
top 23%Funding
top 41%Global
bottom 32%Market
bottom 26%Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Funding: Raised $2.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (Mar 2026)
Global: Single-market focus (Germany)
Audience (LinkedIn): 1k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: C++ Software Developer
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2026Series A$5.9M
- Mar 2026Grant (prize money)$2.9M
- Oct 2023Seed$2.5M
Founders & team
Investors
HTGF, Bmp Ventures, IB Global, GETEC, Europa, European Innovation Council
#10
Seed · Aschaffenburg, Bavaria · founded 2022$3.5Mraised▾
Seed · Aschaffenburg, Bavaria · founded 2022
Developer of small-molecukle therapeutics for cancer. It offers chemically modified RNA nucleotides that prevent the growth of cancer cells and helps treat multiple cancer.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Growth
top 35%Funding
top 44%Talent
bottom 49%Tech
bottom 48%Global
bottom 37%Market
bottom 25%Growth: Fresh capital in last 24 mo
Funding: Raised $3.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Feb 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 717 LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. BaseLaunch and Prof. Distler and Prof. Suzuki) announced in 12 mo
Funding rounds
- Feb 2026Seed$3.5M
Founders & team
Investors
HTGF, LBBW Venture Capital, ONO PHARMACEUTICAL, Mission BioCapital, AbbVie
Tech stack
All In One SeoAnimate.CssApache Http ServerBootstrapCloudflareCloudflare Bot Management
#11
Series D · Munich, Bavaria · founded 2016 · 18 employees$260.6Mraised▾
Series D · Munich, Bavaria · founded 2016 · 18 employees
Developer of drugs for the treatment of cancer. The lead candidate includes CTL-002 which works by neutralizing tumour-produced proteins called GDF-15. It is used to treat cancer and autoimmune disease.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 24%Moat
top 28%Patents
top 42%Innovation
top 45%Growth
top 48%Global
bottom 39%Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) · Last round Series D (Jul 2024)
Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents · Soonicorn
Patents: 23 patents matched (strict assignee match) · 23 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Jul 2024Series D$150M
- Nov 2022Series C$51.3M
- Nov 2020Series B$59.3M
- 2016Seed—
Investors
BioGeneration Ventures, Canaan, Bioqube Ventures, Forbion, Omega Funds, Gilde Healthcare
Tech stack
Animate.CssAosApple Icloud MailContact Form 7Core-JsFont Awesome
#12
Series B · Planegg, Bavaria · founded 2021$29Mraised▾
Series B · Planegg, Bavaria · founded 2021
Developer of programmable DNA therapeutics for a range of medical challenges. The company leverages its proprietary technology to deliver precision medicine solutions, utilizing a programmable DNA-based approach to target specific diseases such as viruses, cancer, and autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Growth
top 35%Funding
top 37%Moat
top 38%Talent
top 38%Tech
top 46%Patents
top 50%Growth: Fresh capital in last 24 mo
Funding: Raised $29.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series B (Sep 2024)
Moat: Editorial + unicorn rating 7/10 · IP moat: 4 patents
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Sep 2024Series B$29M
Founders & team
Investors
BlueYard, SPRIND, Bayern Kapital, Marius Nacht Group
Tech stack
AddtoanyAddtoany Share ButtonsCdnjsCloudflareCloudflare Bot ManagementCookieyes
Funding & investor landscape
$5.9Btotal disclosed funding
64companies funded
196disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Oliver Buck
Founder · ITM
Steffen Schuster
CEO · ITM
Dominik Schumacher
Co-Founder & CEO · Tubulis Technologies
Jonas Helma-Smets
Co-Founder & CSO · Tubulis Technologies
Ulrich Dauer
CEO · Vivoryon
Johanna Holldack
Founder & CEO · Kupando
Guido Baechler
CEO · Mainz BioMed
Christian Sollner
Founder · T-CURX
Johannes Heuckmann
Chief Operating Officer (COO) and founder · DISCO Pharmaceuticals
Roman Thomas
Co-Founder & CEO · DISCO Pharmaceuticals
Tim Pfeiffer
Co-Founder · RAYDIAX
Andre Mewes
Co-Founder · RAYDIAX
Prism market signals · Germany · country-scoped Prism corpus, 2,088,836 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Germany
How research on Oncology & Cancer Therapeutics is moving in Germany
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,712 Germany-affiliated papers.
research sentiment over time
201020182026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 35% → 61% across 2010–2026.
top research entities
- Heidelberg University327
- German Cancer Research Center284
- University Hospital Heidelberg109
- Ludwig-Maximilians-Universität München91
- Friedrich-Alexander-Universität Erlangen-Nürnberg84
leading researchers
Andreas Weigert · Rolf Warta · Salié, Henrike · Marcus Bauer · F Straßheimer · Jasim Kada Benotmane · Bengsch, Bertram · Simon Schallenberg
▲
Breakthroughs583 · 34%
34%→34% share
▲1.0× share momentum1 median citations92% since 2021mostly methods-led
Tumor microenvironment breakthrough research is surging — German papers rose from 12 to 223, with T cell and immune checkpoint topics newly emerging.
rising sub-themes (early→recent)
- Tumor microenvironment12→223
- Immune system7→194
- Immunotherapy8→156
- Cancer research23→166
- Cancer immunotherapy7→88
Newly emergingT cell 0→31 · Pancreatic cancer 0→30 · Immune checkpoint 0→27
Landmark Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibr · 2,055 cites
◆
Advancements758 · 44%
▲ 39%→45% share
▲1.2× share momentum1 median citations92% since 2021mostly empirical
Advancements field-share grew 39%→45%; Tumor microenvironment papers scaled 18→354, with chimeric antigen receptor research newly emerging at 31 papers.
rising sub-themes (early→recent)
- Tumor microenvironment18→354
- Immune system15→288
- Cancer research25→238
- Immunotherapy6→184
- Stromal cell1→43
Newly emergingCancer immunotherapy 0→65 · Transcriptome 0→39 · Chimeric antigen receptor 0→31
Landmark Tumor Microenvironment · 1,206 cites
▼
Concerns189 · 11%
▼ 16%→10% share
▼0.6× share momentum4 median citations85% since 2021mostly reviews
Concern-flagged immunotherapy papers intensified 2→72, while chimeric antigen receptor and T cell safety topics newly emerged in German oncology research.
rising sub-themes (early→recent)
- Immunotherapy2→72
- Tumor microenvironment10→76
- Immune system1→65
- Cancer research6→38
- Cancer immunotherapy1→29
Newly emergingChimeric antigen receptor 0→18 · T cell 0→12 · Antigen 0→11
Landmark Genomic correlates of response to CTLA-4 blockade in metastatic melanoma · 2,936 cites
RESEARCH HOTSPOTS · Germany
Where oncology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Heidelberg331 · +0.54
Munich168 · +0.57
Berlin108 · +0.58
Jülich/Bonn90 · +0.47
Aachen48 · +0.52
Dresden42 · +0.54
Stuttgart9 · +0.38
PATENT SIGNAL · Germany
Who's filing oncology patents in Germany
Germany oncology patent filing is accelerating — 134 filings from 63 assignees (2016–2025), led by Amgen RES Munich, Deutsches Krebsforsch, Vaximm; annual filings 9→15.
134 filings63 assigneespeak 19/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Amgen RES Munich22
- Deutsches Krebsforsch16
- Vaximm14
- UNIV Heidelberg Ruprecht Karls12
- UNIV Tuebingen Medizinische Faku10
- Heidelberg Pharma RES8
- Boehringer Ingelheim INT8
- Mologen8
Common questions
How many Oncology companies are there in Germany?
Radar tracks 155 indexable Oncology companies headquartered in Germany that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Germany?
The Oncology companies in Germany on this list have raised a combined $5.9B in disclosed equity funding across 64 funded companies.
Which is the highest-funded Oncology company in Germany?
CureVac is the highest-funded Oncology company in Germany, with $975.3M in disclosed equity funding.
How many Oncology companies in Germany are funded?
64 of the 155 Oncology companies in Germany on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Germany?
None of the Oncology companies in Germany on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Germany Oncology companies?
The most active investors in Germany Oncology companies on this list include HTGF, Europa, Bmbf, Bayern Kapital, EQT.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.